By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genzyme Corporation 

500 Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-252-7500 Fax: 617-252-7600


About Genzyme

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.

Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.

Learn more at

Follow our jobs on Twitter

Follow us on LinkedIn

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Key Statistics

Ownership: Public

Web Site: Genzyme Corporation
Symbol: GENZ



Medtronic, Inc.  Cardiac Cell Therapy

Cambridge Antibody Technology Group PLC   Antibodies against TGF-ß

Dyax Corp.  Hereditary Angioedema

Alnylam Pharmaceuticals 

Company News
European Commission (EC) Grants Marketing Authorization For Cerdelga® (Eliglustat), Genzyme Corporation (GENZ)’s Oral Therapy For Gaucher Disease Type 1 1/22/2015 10:47:57 AM
Led By Ex-Genzyme Corporation (GENZ) Exec, Isis Pharmaceuticals, Inc. (ISIS)'s Newly Formed Cambridge Subsidiary to Hire 20 1/7/2015 6:36:59 AM
Newly-Approved Keryx Biopharmaceuticals (KERX) Drug Poised to Take About $600 Million of Genzyme Corporation (GENZ)'s Sales 12/31/2014 6:03:43 AM
Genzyme Corporation (GENZ) Exec: Two Big Problems Facing Rare-Disease Biotechs No One Talks About 12/4/2014 8:28:37 AM
First MS Patients In The U.S. Receive Genzyme Corporation (GENZ)’s Lemtrada Following FDA Approval 12/3/2014 8:48:09 AM
Genzyme Corporation (GENZ) Parent Running At ‘Full Speed,’ Chairman Says 11/21/2014 5:56:01 AM
Genzyme Corporation (GENZ) And Isis Pharmaceuticals, Inc. (ISIS) Present KYNAMRO® Clinical Data At American Heart Association 11/19/2014 12:20:46 PM
FDA Approves Genzyme Corporation (GENZ)’s Lemtrada For MS 11/17/2014 6:06:30 AM
PDL BioPharma, Inc. (PDLI) Pays $65.6 Million For Portion Of University of Michigan's Royalty Interest In Genzyme Corporation (GENZ) Drug 11/7/2014 6:00:49 AM
Genzyme Corporation (GENZ) Announces Enrollment Of First Patient In Phase II Vatelizumab Trial In Relapsing Remitting Multiple Sclerosis 11/4/2014 10:46:11 AM